Ginkgo Bioworks Holdings Inc. [DNA] Revenue clocked in at $438.10 million, down -63.90% YTD: What’s Next?


Ginkgo Bioworks Holdings Inc. [NYSE: DNA] loss -2.91% or -0.09 points to close at $3.00 with a heavy trading volume of 17271380 shares. The company report on July 14, 2022 that Ginkgo Bioworks Publishes Inaugural Sustainability Report.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The report, “Caring at Ginkgo,” outlines the company’s approach to sustainability, internal governance structures, and how its cell engineering platform is deployed.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report. The report highlights the company’s vision for and approach to sustainability, includes case studies across its ecosystem, and reports data according to leading environmental, social, and governance (“ESG”) frameworks.

It opened the trading session at $3.14, the shares rose to $3.185 and dropped to $2.90, the range by which the price of stock traded the whole day. The daily chart for DNA points out that the company has recorded -52.08% loss over the past six months. However, it is still -43.54% lower than its most recent low trading price.

If we look at the average trading volume of 23.76M shares, DNA reached to a volume of 17271380 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Ginkgo Bioworks Holdings Inc. [DNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $7.41 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Ginkgo Bioworks Holdings Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 18, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on March 02, 2022, representing the official price target for Ginkgo Bioworks Holdings Inc. stock. Previously, the target price had yet another raise to $7, while Goldman analysts kept a Neutral rating on DNA stock.

The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc. is set at 0.31, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 10.50. The Price to Book ratio for the last quarter was 3.06, with the Price to Cash per share for the same quarter was set at 0.97.

Trading performance analysis for DNA stock

Ginkgo Bioworks Holdings Inc. [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.12. With this latest performance, DNA shares gained by 23.97% in over the last four-week period, additionally sinking by -52.08% over the last 6 months – not to mention a drop of -69.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 52.57, with the RSI for the last a single of trading hit 53.50, and the three-weeks RSI is set at 51.14 for Ginkgo Bioworks Holdings Inc. [DNA]. The present Moving Average for the last 50 days of trading for this stock 2.81, while it was recorded at 3.05 for the last single week of trading, and 6.52 for the last 200 days.

Ginkgo Bioworks Holdings Inc. [DNA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Ginkgo Bioworks Holdings Inc. [DNA] shares currently have an operating margin of -582.43 and a Gross Margin at +53.93. Ginkgo Bioworks Holdings Inc.’s Net Margin is presently recorded at -583.12.

Return on Equity for this stock declined to -243.13, with Return on Assets sitting at -176.62.

Ginkgo Bioworks Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.70 and a Current Ratio set at 10.70.

An analysis of insider ownership at Ginkgo Bioworks Holdings Inc. [DNA]

There are presently around $2,066 million, or 83.60% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: BAILLIE GIFFORD & CO with ownership of 167,752,680, which is approximately 53.269% of the company’s market cap and around 0.50% of the total institutional ownership; GENERAL ATLANTIC, L.P., holding 90,810,814 shares of the stock with an approximate value of $272.43 million in DNA stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $262.07 million in DNA stock with ownership of nearly 35.368% of the company’s market capitalization.

Positions in Ginkgo Bioworks Holdings Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 129 institutional holders increased their position in Ginkgo Bioworks Holdings Inc. [NYSE:DNA] by around 137,144,571 shares. Additionally, 80 investors decreased positions by around 367,510,159 shares, while 27 investors held positions by with 184,075,110 shares. The mentioned changes placed institutional holdings at 688,729,840 shares, according to the latest SEC report filing. DNA stock had 70 new institutional investments in for a total of 19,015,881 shares, while 47 institutional investors sold positions of 22,990,478 shares during the same period.